Treatment of Meticillin‐Resistant <i>Staphylococcus</i> Pyoderma With Rifampicin in 104 Dogs: Clinical Outcomes, Adverse Effects, and Rifampicin Resistance in Nonresponders

Rifampicin at 6 mg/kg is an effective and mostly well-tolerated monotherapy for treating MRSP pyoderma. However, in this study, it was associated with rapid development of resistance in ≥ 10% of treated dogs. Inadequate clinical response occurred without demonstrable resistance in 6.7% of cases. Concurrent use of ciclosporin or fluconazole with rifampicin increased the odds of severe adverse reactions.